开云app官网登录入口网页版-官方正版

#Cure#

32篇内容 | 1101人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1783946, encodeId=662f1e839463c, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Diabetes Obes Metab：DM-CURE风险评分预测2型糖尿病患者心衰, objectType=article, longId=732463, objectId=3182e324630a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3182e324630a, replyNumber=0, likeNumber=96, createdTime=2022-09-22, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3182e324630a, moduleTitle=Diabetes Obes Metab：DM-CURE风险评分预测2型糖尿病患者心衰, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3182e324630a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783947, encodeId=e2cb1e839475d, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=NEJM：单片复方制剂能降低心肌梗死后患者心血管事件复发（SECURE试验）, objectType=article, longId=737183, objectId=2239e3718311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2239e3718311, replyNumber=0, likeNumber=103, createdTime=2022-12-15, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2239e3718311, moduleTitle=NEJM：单片复方制剂能降低心肌梗死后患者心血管事件复发（SECURE试验）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2239e3718311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783945, encodeId=93341e8394591, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Cureus：严重中性粒细胞减少症Graves病的治疗。, objectType=article, longId=299966, objectId=82fe299966ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82fe299966ea, replyNumber=0, likeNumber=87, createdTime=2022-11-09, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82fe299966ea, moduleTitle=Cureus：严重中性粒细胞减少症Graves病的治疗。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=82fe299966ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783943, encodeId=431c1e8394314, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=ICURE用于治疗阿尔茨海默氏症痴呆的多奈哌齐贴剂全球首次获得品种许可批准, objectType=article, longId=220576, objectId=c4e22205e609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e22205e609, replyNumber=0, likeNumber=80, createdTime=2022-06-30, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e22205e609, moduleTitle=ICURE用于治疗阿尔茨海默氏症痴呆的多奈哌齐贴剂全球首次获得品种许可批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4e22205e609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783944, encodeId=567b1e839446e, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Cureus：严重中性粒细胞减少症Graves病的治疗, objectType=article, longId=299560, objectId=6e28299560f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e28299560f4, replyNumber=0, likeNumber=86, createdTime=2022-09-23, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e28299560f4, moduleTitle=Cureus：严重中性粒细胞减少症Graves病的治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6e28299560f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783942, encodeId=90211e8394203, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=CureApp高血压治疗App：2021 ESC大会发布在知名心血管期刊《欧洲心脏杂志》上发表的临床试验结果, objectType=article, longId=217169, objectId=4cb721e16941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cb721e16941, replyNumber=0, likeNumber=130, createdTime=2022-08-13, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cb721e16941, moduleTitle=CureApp高血压治疗App：2021 ESC大会发布在知名心血管期刊《欧洲心脏杂志》上发表的临床试验结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4cb721e16941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783939, encodeId=914b1e83939c3, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=葛兰素史克（GSK）和CureVac制造针对新变体的COVID-19疫苗, objectType=article, longId=206778, objectId=9be9206e7855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9be9206e7855, replyNumber=0, likeNumber=85, createdTime=2021-07-06, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9be9206e7855, moduleTitle=葛兰素史克（GSK）和CureVac制造针对新变体的COVID-19疫苗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9be9206e7855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783940, encodeId=e5031e8394089, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, objectType=article, longId=208907, objectId=e5a320890ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a320890ef2, replyNumber=0, likeNumber=75, createdTime=2021-05-04, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a320890ef2, moduleTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e5a320890ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783938, encodeId=a1361e83938cf, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=CureVac的新冠COVID-19疫苗可在标准冰箱温度下保持稳定3个月, objectType=article, longId=203479, objectId=51112034e9ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51112034e9ff, replyNumber=0, likeNumber=71, createdTime=2021-06-02, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51112034e9ff, moduleTitle=CureVac的新冠COVID-19疫苗可在标准冰箱温度下保持稳定3个月, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=51112034e9ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783941, encodeId=78621e83941fb, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加, objectType=article, longId=212858, objectId=6bb6212858c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bb6212858c0, replyNumber=0, likeNumber=127, createdTime=2021-10-25, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bb6212858c0, moduleTitle=德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6bb6212858c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783937, encodeId=db331e839372b, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=NextCure终止Siglec-15单抗NC318的非小细胞肺癌、卵巢癌单药研究，股价大跌20%, objectType=article, longId=197579, objectId=26cb19e5796b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26cb19e5796b, replyNumber=0, likeNumber=115, createdTime=2020-09-04, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26cb19e5796b, moduleTitle=NextCure终止Siglec-15单抗NC318的非小细胞肺癌、卵巢癌单药研究，股价大跌20%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=26cb19e5796b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783930, encodeId=558e1e8393075, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=股票大涨248%！热烈祝贺陈列平教授！祝贺NextCure！SIGLEC15有望媲美PD-1、PD-L1！, objectType=article, longId=182509, objectId=56161825092c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56161825092c, replyNumber=0, likeNumber=79, createdTime=2020-04-08, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56161825092c, moduleTitle=股票大涨248%！热烈祝贺陈列平教授！祝贺NextCure！SIGLEC15有望媲美PD-1、PD-L1！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56161825092c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783931, encodeId=7c7a1e8393102, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=礼来终止与NextCure公司一年前签订的14亿美元合作协议，后者候选药物为靶向M2巨噬细胞表面的Siglec-15单抗, objectType=article, longId=186460, objectId=2b971864609d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b971864609d, replyNumber=0, likeNumber=61, createdTime=2020-02-01, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b971864609d, moduleTitle=礼来终止与NextCure公司一年前签订的14亿美元合作协议，后者候选药物为靶向M2巨噬细胞表面的Siglec-15单抗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2b971864609d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783936, encodeId=b2411e8393645, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=CureVac的COVID-19候选疫苗可触发免疫反应, objectType=article, longId=194238, objectId=482b194238a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482b194238a0, replyNumber=0, likeNumber=76, createdTime=2020-09-17, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482b194238a0, moduleTitle=CureVac的COVID-19候选疫苗可触发免疫反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=482b194238a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783933, encodeId=560a1e839330a, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Cureus：减轻拔管反应药理剂对拔管质量的影响, objectType=article, longId=188459, objectId=e8e1188459fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8e1188459fd, replyNumber=0, likeNumber=90, createdTime=2020-08-26, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8e1188459fd, moduleTitle=Cureus：减轻拔管反应药理剂对拔管质量的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e8e1188459fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783932, encodeId=28151e839320d, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Cureus：过敏性鼻炎中患者血清中维生素D和血清免疫球蛋白E水平, objectType=article, longId=188443, objectId=6a7c1884438c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a7c1884438c, replyNumber=0, likeNumber=67, createdTime=2020-12-09, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a7c1884438c, moduleTitle=Cureus：过敏性鼻炎中患者血清中维生素D和血清免疫球蛋白E水平, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6a7c1884438c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783935, encodeId=055d1e839359f, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=JAMA：急性冠状动脉综合征患者围术期负荷剂量他汀不能减少1年心血管事件（SECURE-PCI 研究）, objectType=article, longId=191489, objectId=c75c19148929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c75c19148929, replyNumber=0, likeNumber=62, createdTime=2020-09-30, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75c19148929, moduleTitle=JAMA：急性冠状动脉综合征患者围术期负荷剂量他汀不能减少1年心血管事件（SECURE-PCI 研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c75c19148929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783934, encodeId=350e1e8393421, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Cureus：幽门螺杆菌胃炎和功能性消化不良对抑郁症的精神病影响, objectType=article, longId=189323, objectId=280818932347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=280818932347, replyNumber=0, likeNumber=82, createdTime=2020-11-05, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=280818932347, moduleTitle=Cureus：幽门螺杆菌胃炎和功能性消化不良对抑郁症的精神病影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=280818932347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783929, encodeId=ce4f1e839294c, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=3小时暴涨32%！陈列平教授创办的NextCure成功上市, objectType=article, longId=165893, objectId=272216589311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=272216589311, replyNumber=0, likeNumber=72, createdTime=2019-08-09, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=272216589311, moduleTitle=3小时暴涨32%！陈列平教授创办的NextCure成功上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=272216589311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783927, encodeId=07e71e83927e5, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, objectTitle=Cureus：体外冲击波碎石术中不同镇痛药物使用方案比较：随机对照试验, objectType=article, longId=146470, objectId=7fd01464e03e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fd01464e03e, replyNumber=0, likeNumber=83, createdTime=2018-09-26, rootId=0, userName=徐岩, userId=c2b4297, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fd01464e03e, moduleTitle=Cureus：体外冲击波碎石术中不同镇痛药物使用方案比较：随机对照试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7fd01464e03e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Cure

2020-05-29

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Diabetes Obes Metab：DM-CURE风险评分预测2型糖尿病患者心衰

2022-09-22

徐岩 (审核中...)

前往app查看评论内容

#Cure#

NEJM：单片复方制剂能降低心肌梗死后患者心血管事件复发（SECURE试验）

2022-12-15

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Cureus：严重中性粒细胞减少症Graves病的治疗。

2022-11-09

徐岩 (审核中...)

前往app查看评论内容

#Cure#

ICURE用于治疗阿尔茨海默氏症痴呆的多奈哌齐贴剂全球首次获得品种许可批准

2022-06-30

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Cureus：严重中性粒细胞减少症Graves病的治疗

2022-09-23

徐岩 (审核中...)

前往app查看评论内容

#Cure#

CureApp高血压治疗App：2021 ESC大会发布在知名心血管期刊《欧洲心脏杂志》上发表的临床试验结果

2022-08-13

徐岩 (审核中...)

前往app查看评论内容

#Cure#

葛兰素史克（GSK）和CureVac制造针对新变体的COVID-19疫苗

2021-07-06

徐岩 (审核中...)

前往app查看评论内容

#Cure#

CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点

2021-05-04

徐岩 (审核中...)

前往app查看评论内容

#Cure#

CureVac的新冠COVID-19疫苗可在标准冰箱温度下保持稳定3个月

2021-06-02

徐岩 (审核中...)

前往app查看评论内容

#Cure#

德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加

2021-10-25

徐岩 (审核中...)

前往app查看评论内容

#Cure#

NextCure终止Siglec-15单抗NC318的非小细胞肺癌、卵巢癌单药研究，股价大跌20%

2020-09-04

徐岩 (审核中...)

前往app查看评论内容

#Cure#

股票大涨248%！热烈祝贺陈列平教授！祝贺NextCure！SIGLEC15有望媲美PD-1、PD-L1！

2020-04-08

徐岩 (审核中...)

前往app查看评论内容

#Cure#

礼来终止与NextCure公司一年前签订的14亿美元合作协议，后者候选药物为靶向M2巨噬细胞表面的Siglec-15单抗

2020-02-01

徐岩 (审核中...)

前往app查看评论内容

#Cure#

CureVac的COVID-19候选疫苗可触发免疫反应

2020-09-17

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Cureus：减轻拔管反应药理剂对拔管质量的影响

2020-08-26

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Cureus：过敏性鼻炎中患者血清中维生素D和血清免疫球蛋白E水平

2020-12-09

徐岩 (审核中...)

前往app查看评论内容

#Cure#

JAMA：急性冠状动脉综合征患者围术期负荷剂量他汀不能减少1年心血管事件（SECURE-PCI 研究）

2020-09-30

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Cureus：幽门螺杆菌胃炎和功能性消化不良对抑郁症的精神病影响

2020-11-05

徐岩 (审核中...)

前往app查看评论内容

#Cure#

3小时暴涨32%！陈列平教授创办的NextCure成功上市

2019-08-09

徐岩 (审核中...)

前往app查看评论内容

#Cure#

Cureus：体外冲击波碎石术中不同镇痛药物使用方案比较：随机对照试验

2018-09-26

科室
- - 订阅+
  - 更多科室
工具
服务